Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China.

Journal: Asian journal of urology
Published Date: Sep 23, 2019

Abstract

OBJECTIVE: To establish non-inferiority of gonadotropin-releasing hormone degarelix compared with goserelin in suppressing and maintaining castrate testosterone levels from Day 28 to Day 364 in Chinese patients with prostate cancer.

Authors

  • Yinghao Sun
    Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China.
  • Liping Xie
    Department of Urology, First Affiliated Hospital, Zhejiang University, Hangzhou, China.
  • Tao Xu
    Department of Urology, Peking University People's Hospital, Beijing, China.
  • Jørn S Jakobsen
    Global Clinical Research and Development, Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
  • Weiqing Han
    Department of Urology, Hunan Cancer Hospital, Hunan Province, China.
  • Per S Sørensen
    Global Clinical Research and Development, Ferring Pharmaceuticals A/S, Copenhagen, Denmark.
  • XiaoFeng Wang
    Indiana University Bloomington.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals